The BioFire® Respiratory 2.1-EZ
(RP2.1- EZ) Panel (EUA)*
Product not available outside U.S.A.
Now authorized by the FDA through an Emergency Use Authorization, the BioFire RP2.1-EZ Panel (EUA)* uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes. As a healthcare provider, this means your patients can receive the right treatment the first time, leading to shorter appointment times and improved antimicrobial stewardship.1 The BioFire RP2.1-EZ Panel (EUA)* is designed to run on the BioFire® FilmArray® 2.0 EZ Configuration System, which is intended to be used in near-patient settings.1,2